person · Reporting owner

Derovan Netanel

Disclosed activity across 1 company

Tapewire entity: 112968
SEC CIK: 0001901330

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
ORAMED PHARMACEUTICALS INC.ORMP · Entity 6311	Chief Legal Officer	May 26, 2023	May 31, 2023

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

ORAMED PHARMACEUTICALS INC.

Report date May 26, 2023 · Filed May 31, 2023

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	149,500	Reported balance After 2023-05-26 transaction · row 1 1 source row Row 1 · 2023-05-26 · Grant · Acquired 20,500 · Balance 149,500 F1: Restricted Stock Units ("RSUs") granted in April 2023 and vested upon achievement of certain performance conditions. The RSUs converted into Issuer's common stock on a one-for-one basis.

Filing footnotes · ownership attribution and instrument terms

F1: Restricted Stock Units ("RSUs") granted in April 2023 and vested upon achievement of certain performance conditions. The RSUs converted into Issuer's common stock on a one-for-one basis.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
May 26, 2023 Filed May 31, 2023 21:10 UTC	ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311	GrantCommon Stock	20,500	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-23-033144 · doc4.xml · nonDerivative · entry 1 Derovan Netanel · CIK 0001901330 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 149,500 F1 · price: Restricted Stock Units ("RSUs") granted in April 2023 and vested upon achievement of certain performance conditions. The RSUs converted into Issuer's common stock on a one-for-one basis. Read SEC document
April 17, 2023 Filed Apr 20, 2023 10:00 UTC	ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311	GrantCommon Stock	81,000	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-23-024941 · doc4.xml · nonDerivative · entry 1 Derovan Netanel · CIK 0001901330 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 129,000 F1 · price: Represents Restricted Stock Units ("RSUs") that will vest in equal quarterly installments of 6,750 over a three year period starting May 1, 2023. The RSUs convert into the Issuer's Common Stock on a one-for-one basis. Read SEC document
July 28, 2022 Filed Aug 2, 2022 00:00 UTC	ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311	GrantCommon Stock	30,000	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-22-043770 · doc4.xml · nonDerivative · entry 1 Derovan Netanel · CIK 0001901330 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,000 F1 · price: Represents Restricted Stock Units ("RSUs") that will vest in 3 installments as follows: 10,000 shall vest on each of January 1, 2024, January 1, 2025 and January 1, 2026. The RSUs convert into the Issuer's Common Stock on a one-for-one basis. Read SEC document
January 09, 2022 Filed Jan 12, 2022 01:40 UTC	ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311	GrantStock Option (right to buy) · Derivative	30,000	$0.00 Strike: $12.03	$0.00	Disclosure SEC source: 0001213900-22-001617 · ownership.xml · derivative · entry 2 Derovan Netanel · CIK 0001901330 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2032-01-03 F2 · derivative.exercise_date: The Stock Option will vest in 4 installments as follows: 7,500 shall vest on each of January 1, 2023, January 1, 2024, January 1, 2025 and January 1, 2026. Read SEC document
January 09, 2022 Filed Jan 12, 2022 01:40 UTC	ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311	GrantCommon Stock	18,000	Not disclosed	Not disclosed	Disclosure SEC source: 0001213900-22-001617 · ownership.xml · nonDerivative · entry 1 Derovan Netanel · CIK 0001901330 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,000 F1 · price: Represents Restricted Stock Units ("RSUs") that will vest in 4 installments as follows: 4,500 shall vest on each of January 1, 2023, January 1, 2024, January 1, 2025 and January 1, 2026. The RSUs convert into the Issuer's Common Stock on a one-for-one basis. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.